In immunotherapy, TSAs are used to train the immune system to recognize and attack cancer cells. Approaches include the development of personalized cancer vaccines that stimulate the patient's immune system to target TSAs. Additionally, adoptive cell therapies, such as TCR therapy, involve engineering T cells to specifically recognize and attack cells expressing TSAs. These therapies have shown promising results in various types of cancers.
